Zenith Epigenetics Reports Advancement of ZEN-3694 in NUT Carcinoma
Zenith's BET inhibitor ZEN-3694 providing significant clinical benefit in patients with aggressive cancer type
- Calgary, Alberta--(Newsfile Corp. - June 1, 2023) - Zenith Epigenetics Ltd. ("Zenith" or the "Company") reports clinical activity and the advancement in development of its BET inhibitor (BETi) ZEN-3694 in patients with NUT carcinoma (NC).
- Zenith Epigenetics has provided ZEN-3694 to two NC patients for compassionate use and both experienced significant clinical benefit and durable reduction of their tumors.
- "We are very pleased that NUT carcinoma patients receiving ZEN-3694 for compassionate use have benefitted from our drug," said Donald McCaffrey, CEO of Zenith Epigenetics.
- We continue to advance these programs with our partners and are committed to bring this important therapy to these patients."